版权说明 帮助中心
首页 > 成果 > 详情

Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.

SCI-EMedline
WOS被引频次:10
认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Liu, Qingyun;Hu, Yijun;Yu, Honghua;Yuan, Ling;Hu, Jie;Atik, Alp;Guan, Meng;Li, Dongli;Li, Xin;Tang, Shibo*
通讯作者:
Tang, Shibo
作者机构:
[Liu, Qingyun] Tongliao City Hosp, Dept Ophthalmol, Tongliao, Peoples R China.
[Hu, Jie; Hu, Yijun] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
[Atik, Alp; Hu, Yijun] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Yu, Honghua] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
[Guan, Meng; Li, Dongli; Yuan, Ling] Kunming Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Kunming, Peoples R China.
通讯机构:
[Tang, Shibo] Cent S Univ, Aier Sch Ophthalmol, Fourth Floor,198 Middle Furong Rd, Changsha 410015, Hunan, Peoples R China.
语种:
英文
关键词:
CSME;DME;bevacizumab;triamcinolone acitonide;OCT
期刊:
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
ISSN:
0275-004X
年:
2015
卷:
35
期:
2
页码:
272-279
文献类别:
WOS:Article
所属学科:
ESI学科类别:临床医学;WOS学科类别:Ophthalmology
入藏号:
基金类别:
National Natural Science Foundation of China [81260151]; Applied Basic Research Foundation of the Department of Science and Technology of Yunnan Province [2011FB062]; Science and Technology Foundation of the Department of Health of Yunnan Province [2011WS0041]
机构署名:
本校为通讯机构
院系归属:
爱尔眼科学院
摘要:
OBJECTIVES:: To evaluate the short-term efficacy of triamcinolone acetonide versus bevacizumab for the treatment of diabetic, clinically significant, macular edema with different optical coherence tomography findings. METHODS:: Fifty eyes of 45 consecutive patients with diabetic, clinically significant, macular edema were incorporated in this prospective interventional case series. Patients were divided into 3 groups according to findings on optical coherence tomography: 1) macular edema combined with serous retinal detachment (Group 1), 2) diffused macular thickening (Group 2), and 3) cystoid macular edema (Group 3). Patients from each group were treated with a single intravitreal injection of triamcinolone (IVTA) or 2 intravitreal injections of bevacizumab (IVB) with an interval of 6 weeks. Patients were observed at 6, 12, and 24 weeks after IVTA or the first IVB injection. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were examined at each visit. Repeated-measures analysis of variance was used to compare the efficacy of the treatment groups. RESULTS:: In Group 1, IVTA showed more favorable effects on CRT reduction and BCVA improvement compared with IVB at 6, 12, and 24 weeks (P = 0.002, 0.001, 0.027 and P = 0.036, 0.001, 0.027), respectively. In Group 2, IVB had more CRT reduction than IVTA at 6 and 12 weeks (P = 0.013 and 0.036), although there was no significant difference in BCVA improvement between the 2 groups (P > 0.05). In Group 3, IVTA and IVB did not have significant effects on CRT reduction and BCVA improvement (P > 0.05). CONCLUSION:: The short-term efficacy of IVTA and IVB on treating clinically significant macular edema varied with different optical coherence tomography findings. In clinically significant macular edema combined with serous retinal detachment, IVTA may be more favorable than IVB in CRT reduction and BCVA improvement. In patients with diffused macular thickening, IVB may be better than IVTA in macular thickness reduction, although this does not translate to a significant improvement in BCVA. Copyright © by Ophthamic Communications Society.
参考文献:
Astam Neslihan, 2009, International Ophthalmology, V29, P343, DOI 10.1007/s10792-008-9242-2
Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
FINE BS, 1981, AM J OPHTHALMOL, V92, P466, DOI 10.1016/0002-9394(81)90638-3

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com